Patents Assigned to Laboratoire Francais du Fractionnement et des Biotechnologies
  • Antibody method for treatment of a disease in which the target cells are cells which express CD20
    Patent number: 9873745
    Abstract: The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: January 23, 2018
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christophe De Romeuf, Christine Gaucher, Jean-Luc Teillaud, Jean-Francois Prost
  • MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION
    Publication number: 20180002442
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: June 7, 2017
    Publication date: January 4, 2018
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: ROLAND BELIARD, Dominique BOUREL, Arnaud GLACET, Christophe de ROMEUF, Nicolas BIHOREAU, Emmanuel NONY
  • Method for purifying active GLA-domain coagulation proteins
    Patent number: 9850477
    Abstract: The invention relates to a method for purifying biologically active GLA-domain coagulation proteins, comprising the following steps: a) bringing a sample that contains one or more GLA-domain coagulation proteins and may contain biologically inactive molecules of GLA-domain protein(s), into contact with an affinity support on which nucleic aptamers that bind specifically to at least one biologically active GLA-domain coagulation protein are immobilized, in order to form complexes between (i) said nucleic aptamers and (ii) said GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering said biologically active GLA-domain coagulation protein(s) in a purified form.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: December 26, 2017
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Gerard Perret, Nicolas Bihoreau, Laurent Siret
  • Method for immobilizing nucleic ligands
    Patent number: 9803184
    Abstract: The invention relates to a method for immobilizing nucleic ligands including at least one reactive amine function, by grafting on an activated solid substrate, including a step of coupling said nucleic acids on said activated solid substrate having a pH of less than 6.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: October 31, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Egisto Boschetti, Gérald Perret
  • BIOLOGICAL GLUE AND USE THEREOF AS A MEDICAMENT
    Publication number: 20170296694
    Abstract: Disclosed is a thrombin-free, liquid biological glue for therapeutic use, including fibrinogen and factor VIIa. The ratio of fibrinogen concentration to FVIIa concentration is 20000:1 to 1000:1, with the concentrations being expressed in weight per volume. The fibrinogen concentration is lower than 60 mg/ml. Also disclosed are a kit for preparing such a biological glue, a method to prepare the glue, and a medicament.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 19, 2017
    Applicant: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Abdessatar Sami CHTOUROU, Jean-Luc PLANTIER
  • METHOD FOR PREPARING UNIVERSAL PLASMA
    Publication number: 20170281679
    Abstract: The present invention relates to an universal plasma, originating from a mixture of plasmas originating from donor individuals of blood groups A, B, AB and/or O and compatible with all the blood groups and the preparation process thereof.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 5, 2017
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Abdessatar Chtourou
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9718890
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 1, 2017
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Method for preparing a concentrate of polyvalent immunoglobulin
    Patent number: 9718856
    Abstract: The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: August 1, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Abdessatar Chtourou, Damien Bataille, Georges Michaux
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9718889
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: August 1, 2017
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Amaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9708409
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 18, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Use of antidotes to coagulation inhibitors indicated in the prevention or treatment of thromboembolic pathologies
    Patent number: 9700603
    Abstract: The use of factor Xa in the prevention or treatment in a patient, in particular a human being or an animal, of haemorrhagic events induced by taking anticoagulants.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: July 11, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Jean-Luc Plantier, Meyer-Michel Samama
  • Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
    Patent number: 9694071
    Abstract: Highly effective combinations of a compound of formula A (a PI3K? selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K? and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: July 4, 2017
    Assignees: TG Therapeutics, Inc., Rhizen Pharmaceuticals NA, Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K. V. S. Vakkalanka
  • PRODUCTION OF FC FRAGMENTS
    Publication number: 20170129966
    Abstract: In one aspect, the disclosure provides cells and transgenic non-human mammals for the production of Fc fragments, as well as compositions and uses thereof.
    Type: Application
    Filed: June 2, 2015
    Publication date: May 11, 2017
    Applicant: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventor: Nicholas C. Masiello
  • ORAL COMPOSITION OF ANTI-TNF ALPHA ANTIBODIES
    Publication number: 20170121402
    Abstract: The present invention relates to a pharmaceutical composition for oral delivery, including an anti tumour necrosis factor alpha (TNF?) antibody, preferably a monoclonal antibody produced in the milk of a transgenic non-human animal, and which can be combined advantageously with caprylic acid, and is preferably in a form that is suitable for targeted release of the antibody in the intestine.
    Type: Application
    Filed: June 18, 2015
    Publication date: May 4, 2017
    Applicant: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventor: Abdessatar Sami Chtourou
  • Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
    Patent number: 9637544
    Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: May 2, 2017
    Assignees: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, UNIVERSITE MONTPELLIER I, CENTRE NATIONAL DE LUTTE CONTRE LE CANCER, I.N.S.E.R.M. (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Christian Behrens, Isabelle Navarro-Teulon
  • Transcription unit and use thereof in expression vectors
    Patent number: 9551009
    Abstract: A transcription unit constituted by a polynucleotide including the hCMVie virus enhancer, the enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and essentially having transcription activation properties, and the promoter region of Cyclin-Dependent Kinase 9 (CDK9), the promoter region having the nucleotide sequence SEQ ID NO: 2, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 2 and essentially having a promoter activity.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: January 24, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, Francois Coutard
  • Affinity substrate and methods for selectively purifying a blood plasma protein
    Patent number: 9534012
    Abstract: An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: January 3, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Gerald Perret, Michel Nogre
  • Transcription units and the use thereof in expression vectors
    Patent number: 9512230
    Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: December 6, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, Francois Coutard
  • Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II
    Patent number: 9511138
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 6, 2016
    Assignees: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE REGIONAL DE LUTTE CONTRE LE CANCER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE MONTPELLIER 1
    Inventors: Christine Gaucher, Isabelle Navarro-Teulon
  • Optimized FC variants
    Patent number: RE46585
    Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 24, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars